Edouard Forcade

Oct 24, 2024 | nature.com | Ana Alarcon Tomas |Edouard Forcade |Vladan Vucinic |Nicolaus Kröger |Lucía López Corral |Jan Vydra | +10 more

Chimeric antigen receptor (CAR) T-cells have ushered in a new era of adoptive cell immunotherapies and caused a paradigm shift in the treatment of relapsed and refractory B-cell lymphomas [1].

Aug 1, 2024 | nature.com | Myriam Labopin |Depei Wu |Mahmoud Aljurf |Edouard Forcade |Jakob Passweg |Thomas Pabst | +7 more

AbstractCore-binding factor acute myeloid leukemia (CBF-AML) represents 12–15% of all AML cases. Although CBF positivity infers a survival advantage, overall survival (OS) remains dismal. Treatment is with cytarabine/anthracycline-based chemotherapy induction followed by high-dose cytarabine (HiDAC) consolidation. Allogeneic hematopoietic stem cell transplantation (allo-SCT) is reserved for relapse or for patients having not achieved MRD-negativity at high risk for relapse.

Dec 12, 2023 | nature.com | Xavier Poiré |Myriam Labopin |Gerard Socie |Edouard Forcade |Yves Chalandon |Mahmoud Aljurf | +3 more

AbstractAllogeneic hematopoietic cell transplantation (allo-HCT) remains the best consolidation strategy for acute myeloid leukemia (AML) with complex karyotype (CK). However, CK is a heterogenous and highly diverse entity. Numerical abnormalities have been associated with a controversial prognosis and AML with only multiple numerical abnormalities known as pure hyperdiploid karyotype (HDK) may have a distinct prognosis after allo-HCT compared to non-pure HDK CK AML.

Mar 28, 2023 | nature.com | Olivier Tournilhac |Peter Dreger |Vladan Vucinic |Pavel Jindra |Patrice Chevallier |Edouard Forcade | +6 more

AbstractAllogeneic transplantation (allo-HCT) is a curative treatment in CLL whose efficacy including the most severe forms had led to the 2006 EBMT recommendations. The advent after 2014 of targeted therapies has revolutionized CLL management, allowing prolonged control to patients who have failed immunochemotherapy and/or have TP53 alterations. We analysed the pre COVID pandemic 2009–2019 EBMT registry.